Chattem Q3 predictions
This article was originally published in The Tan Sheet
Executive Summary
Third quarter total revenue expected to reach $65 mil.-$67 mil., compared with previous guidance of $61 mil.-$63 mil. and year-ago sales of $49.6 mil., consumer products firm says in preliminary earnings release Sept. 12. "Strong results" were driven by Icy Hot, pHisoderm, Dexatrim and Gold Bond, "all of which experienced double-digit sales increases" over last year's Q3, Chattem says. EBITDA should reach $16 mil.-$17 mil. in Q3, compared with $11.3 mil. last year, firm predicts. FY 2003 revenue growth of 6%-8% is expected. Chattem will hold an earnings call on Sept. 27 to disclose full financial results, discuss its exit from ephedra market (1"The Tan Sheet" Sept. 9, 2002, p. 4)...
You may also be interested in...
Chattem Exiting Ephedra Market With Dexatrim Reformulations
Chattem is getting out of the ephedra business and is set to ship three reformulated Dexatrim SKUs by the end of September
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.